
Nekkar - Q1 Review – Short-Term Softness, Fundamentals Intact

Redeye returns with an updated view following Nekkar's Q1 figures that was surprisingly soft even if volatility should be expected. We cut mainly H1'25 figures while expecting a recovery in H2'25. The tender pipeline continued to grow, and a few deals could easily offset our current estimates. Despite the quarterly volatility, the fundamentals continue to strengthen, supporting our positive long-term view.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Nekkar - Q1 Review – Short-Term Softness, Fundamentals Intact